February 19, 2008 - Quest Diagnostics Inc. announced that it has licensed rights to uses of the Septin 9 DNA methylation biomarker from Epigenomics AG (Frankfurt, Germany), a cancer molecular diagnostics company, to develop a molecular-based laboratory test designed to help physicians detect colorectal cancer based on a patient’s blood specimen.
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now